Ichio Aoki
YOU?
Author Swipe
View article: Antiemesis Corticosteroids Potentiate Checkpoint Blockade Efficacy by Normalizing the Immune Microenvironment in Metastatic Murine Breast Cancer
Antiemesis Corticosteroids Potentiate Checkpoint Blockade Efficacy by Normalizing the Immune Microenvironment in Metastatic Murine Breast Cancer Open
Glucocorticoid steroids are widely prescribed in oncology for managing treatment‐related side effects, though their use is discouraged in patients undergoing immune checkpoint blockade (ICB). Given the crucial role of steroids in supportiv…
View article: Multi-spin Redox Sensor for Electron Paramagnetic Resonance Studies of Tissue Redox State <i>In Vivo</i>: Validation of Data With a Conventional Spin Probe
Multi-spin Redox Sensor for Electron Paramagnetic Resonance Studies of Tissue Redox State <i>In Vivo</i>: Validation of Data With a Conventional Spin Probe Open
Using a non-toxic nanoparticle in the chemical structure of RS as a carrier of nitroxide residues would enhance its translational relevance.
View article: Quantification of Oxygenation and Oxygen Consumption Rates in the Mouse Brain Based on Tissue Oxygen Level‐Dependent (TOLD) MRI
Quantification of Oxygenation and Oxygen Consumption Rates in the Mouse Brain Based on Tissue Oxygen Level‐Dependent (TOLD) MRI Open
A noninvasive method to estimate oxygenation and oxygen (O 2 ) consumption rates in mouse brain tissue based on T 1 ‐weighted tissue oxygen level‐dependent (TOLD) MRI was developed. The aim of the present study was to estimate the kinetics…
View article: An Electron Paramagnetic Resonance Study of the Superoxide-Scavenging and Redox-Modulating Effects of Lecithinized Superoxide Dismutase in the Bloodstream
An Electron Paramagnetic Resonance Study of the Superoxide-Scavenging and Redox-Modulating Effects of Lecithinized Superoxide Dismutase in the Bloodstream Open
Lecithinized superoxide dismutase (PC-SOD) was found to have a significantly improved half-life in the bloodstream and better pharmacological effects compared with unmodified SOD. However, there is no direct evidence that parenterally admi…
View article: 2-Nitroimidazole-Functionalized Superparamagnetic Iron Oxide Nanoparticles Detect Hypoxic Regions of Glioblastomas on MRI and Improve Radiotherapy Efficacy
2-Nitroimidazole-Functionalized Superparamagnetic Iron Oxide Nanoparticles Detect Hypoxic Regions of Glioblastomas on MRI and Improve Radiotherapy Efficacy Open
The presence of hypoxic regions in tumors is associated with malignancy and is an important target for the high-precision diagnosis and treatment of tumors. Radioresistant hypoxic regions can be precisely identified and treated without the…
View article: Brain morphological analysis in mice with hyperactivation of the hedgehog signaling pathway
Brain morphological analysis in mice with hyperactivation of the hedgehog signaling pathway Open
Hedgehog signaling is a highly conserved pathway that plays pivotal roles in morphogenesis, tumorigenesis, osteogenesis, and wound healing. Previous investigations in patients with Gorlin syndrome found low harm avoidance traits, and incre…
View article: Albumin nanoparticle electrostatically loaded with highly anionic Gd-thiacalixarene complex for MRI-guided neutron capture therapy
Albumin nanoparticle electrostatically loaded with highly anionic Gd-thiacalixarene complex for MRI-guided neutron capture therapy Open
As a neutron capture therapy (NCT) agent, 157Gd garners significant attention due to the largest neutron capture cross section, emission of γ rays and Auger electrons, and facilitation of magnetic resonance imaging-guided NCT. Owing to its…
View article: EFFECTS OF HIGH-LET RADIOTHERAPY ON ORTHOTOPIC GLIOMA MOUSE MODEL
EFFECTS OF HIGH-LET RADIOTHERAPY ON ORTHOTOPIC GLIOMA MOUSE MODEL Open
View article: Self‐Folding Macromolecular Drug Carrier for Cancer Imaging and Therapy (Adv. Sci. 7/2024)
Self‐Folding Macromolecular Drug Carrier for Cancer Imaging and Therapy (Adv. Sci. 7/2024) Open
Self‐Folding Macromolecular Drug Carrier In article number 2304171, Gao Shan, Yutaka Miura, Nobuhiro Nishiyama, and their colleagues utilize a self‐folding macromolecular drug carrier (SMDC) for theranostics applications. The cover image d…
View article: Block Copolymer‐Stabilized Metal–Organic Framework Hybrids Loading Pd Nanoparticles Enable Tumor Remission Through Near‐Infrared Photothermal Therapy
Block Copolymer‐Stabilized Metal–Organic Framework Hybrids Loading Pd Nanoparticles Enable Tumor Remission Through Near‐Infrared Photothermal Therapy Open
Photothermal Therapy In article number 2300107, Jiashing Yu, Kevin C.-W. Wu, Horacio Cabral, and co-workers use a nanosized metal–organic framework (MOF) to generate palladium nanoparticles within the MOF structure for producing phototherm…
View article: Development of autonomous tracking and carrying functions for harvest support robots
Development of autonomous tracking and carrying functions for harvest support robots Open
View article: Block Copolymer‐Stabilized Metal–Organic Framework Hybrids Loading Pd Nanoparticles Enable Tumor Remission Through Near‐Infrared Photothermal Therapy
Block Copolymer‐Stabilized Metal–Organic Framework Hybrids Loading Pd Nanoparticles Enable Tumor Remission Through Near‐Infrared Photothermal Therapy Open
Metal–organic frameworks (MOFs), such as the magnetic resonance imaging‐fit MIL‐100 based on Fe, are gaining significant attention as versatile theranostics with high‐loading capability. Moreover, as MOFs can be engineered to target tumors…
View article: Self‐Folding Macromolecular Drug Carrier for Cancer Imaging and Therapy
Self‐Folding Macromolecular Drug Carrier for Cancer Imaging and Therapy Open
Nano‐sized contrast agents (NCAs) hold potential for highly specific tumor contrast enhancement during magnetic resonance imaging. Given the quantity of contrast agents loaded into a single nano‐carrier and the anticipated relaxation effec…
View article: Tolerable treatment of glioblastoma with redox-cycling ‘mitocans': a comparative study in vivo
Tolerable treatment of glioblastoma with redox-cycling ‘mitocans': a comparative study in vivo Open
Objectives: The present study describes a pharmacological strategy for the treatment of glioblastoma by redoxcycling 'mitocans' such as quinone/ascorbate combination drugs, based on their tumor-selective redox-modulating effects and…
View article: Redox-Cycling “Mitocans” as Effective New Developments in Anticancer Therapy
Redox-Cycling “Mitocans” as Effective New Developments in Anticancer Therapy Open
Our study proposes a pharmacological strategy to target cancerous mitochondria via redox-cycling “mitocans” such as quinone/ascorbate (Q/A) redox-pairs, which makes cancer cells fragile and sensitive without adverse effects on normal cells…
View article: Supplementary Figure from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma
Supplementary Figure from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma Open
Supplementary Figure S1-S7
View article: Supplementary Table from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma
Supplementary Table from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma Open
Supplementary Table S1-S12
View article: Supplementary Data from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma
Supplementary Data from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma Open
Supplementary document
View article: Data from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma
Data from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma Open
Primary central nervous system lymphoma (PCNSL) is an isolated type of lymphoma of the central nervous system and has a dismal prognosis despite intensive chemotherapy. Recent genomic analyses have identified highly recurrent mutations of …
View article: Supplementary Table from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma
Supplementary Table from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma Open
Supplementary Table S1-S12
View article: Data from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma
Data from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma Open
Primary central nervous system lymphoma (PCNSL) is an isolated type of lymphoma of the central nervous system and has a dismal prognosis despite intensive chemotherapy. Recent genomic analyses have identified highly recurrent mutations of …
View article: Supplementary Data from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma
Supplementary Data from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma Open
Supplementary document
View article: Supplementary Figure from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma
Supplementary Figure from A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma Open
Supplementary Figure S1-S7
View article: Supplementary Figure 2 from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model
Supplementary Figure 2 from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model Open
Supplementary Figure 2 from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model
View article: Data from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model
Data from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model Open
Nanoparticle therapeutics are promising platforms for cancer therapy. However, it remains a formidable challenge to assess their distribution and clinical efficacy for therapeutic applications. Here, by using multifunctional polymeric mice…
View article: Data from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model
Data from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model Open
Nanoparticle therapeutics are promising platforms for cancer therapy. However, it remains a formidable challenge to assess their distribution and clinical efficacy for therapeutic applications. Here, by using multifunctional polymeric mice…
View article: Supplementary Figure 2 from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model
Supplementary Figure 2 from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model Open
Supplementary Figure 2 from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model
View article: Supplementary Methods from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model
Supplementary Methods from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model Open
Supplementary Methods from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model
View article: Supplementary Figure 1 from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model
Supplementary Figure 1 from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model Open
Supplementary Figure 1 from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model
View article: Supplementary Table 2 from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model
Supplementary Table 2 from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model Open
Supplementary Table 2 from Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model